“This document represents a collective effort to refine and advance the standards of care in STEMI management," according to one cardiologist behind the project. 

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Reliability modeling suggests the small-diameter defibrillation lead, already linked to positive early outcomes, should last patients for at least 10 years—and likely longer. 

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

The FDA clearly sees significant potential in this new screening software from New York-based AccurKardia.

A new study found cumulative radiation exposure of 16 mSv to red bone marrow can cause an increased rate of some hematological malignancies.

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.